Gene · 3702
Papers2,789
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
721 to 740 of 2,789
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Tumor-infiltrating lymphocytes are functionally inactivated by CD90+ stromal cells and reactivated by combined Ibrutinib and Rapamycin in human pleural mesothelioma. | Theranostics | 2022 | 34987640 | PubTator, text mining | PubMed |
| Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants. | Microbiol Spectr | 2022 | 34985303 | PubTator, text mining | PubMed |
| Screening and analysis of RNAs associated with activated memory CD4 and CD8 T cells in liver cancer. | World J Surg Oncol | 2022 | 34980144 | PubTator, text mining | PubMed |
| Therapy-Related Transcriptional Subtypes in Matched Primary and Recurrent Head and Neck Cancer. | Clin Cancer Res | 2022 | 34965946 | PubTator, text mining | PubMed |
| Is a BTKi or BCL2i preferable for first "novel" therapy in CLL? The case for BTKis. | Blood Adv | 2022 | 34965291 | PubTator, text mining | PubMed |
| Epithelial-mesenchymal transition interaction with CD8+ T cell, dendritic cell and immune checkpoints in the development of melanoma. | Cancer Biomark | 2022 | 34957999 | PubTator, text mining | PubMed |
| The Conformational State of the BTK Substrate PLCγ Contributes to Ibrutinib Resistance. | J Mol Biol | 2022 | 34954235 | PubTator, text mining | PubMed |
| Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients. | Blood Adv | 2022 | 34941990 | PubTator, text mining | PubMed |
| Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. | Haematologica | 2022 | 34937320 | PubTator, text mining | PubMed |
| Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study. | Br J Haematol | 2022 | 34915592 | PubTator, text mining | PubMed |
| Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features. | Target Oncol | 2022 | 34905129 | PubTator, text mining | PubMed |
| Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies. | Mol Oncol | 2022 | 34861096 | PubTator, text mining | PubMed |
| Reciprocal SH2-SH3 Domain Contacts between ITK Molecules Limit T Cell Receptor Signaling in Th2-type CD4+ T Cells. | Immunol Invest | 2022 | 34844506 | PubTator, text mining | PubMed |
| Age-related Differences in the Nasal Mucosal Immune Response to SARS-CoV-2. | Am J Respir Cell Mol Biol | 2022 | 34731594 | PubTator, text mining | PubMed |
| Tumor-Cell-Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody-Inhibitor Conjugates (AiCs). | Angew Chem Int Ed Engl | 2022 | 34725904 | PubTator, text mining | PubMed |
| The role of PI3'-lipid signalling in melanoma initiation, progression and maintenance. | Exp Dermatol | 2022 | 34717019 | PubTator, text mining | PubMed |
| Reactivities of the Front Pocket N-Terminal Cap Cysteines in Human Kinases. | J Med Chem | 2022 | 34647463 | PubTator, text mining | PubMed |
| Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma. | Blood Adv | 2022 | 34638136 | PubTator, text mining | PubMed |
| Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. | Haematologica | 2022 | 34587719 | PubTator, text mining | PubMed |
| Exposure-response analysis of acalabrutinib and its active metabolite, ACP-5862, in patients with B-cell malignancies. | Br J Clin Pharmacol | 2022 | 34532877 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3702/papers?page=37